Breast Cancer Profiling using Real-Time PCR Techniques

Journal of Clinical Ligand Assay

Volumn 26, Issue 4, 2004, Pages 191-195

  Perreard, Laurent ^b   Robison, John E ^a   Bastien, Roy R L ^a   Bernard, Philip S ^a,c  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP LABORATORIES   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

Breast cancer; FFPE; Microarray; Molecular diagnostics; Real time PCR

Indexed keywords

ALGORITHM; BIOTECHNOLOGY; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CANCER STAGING; CONFERENCE PAPER; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DNA FINGERPRINTING; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; GENOMICS; HISTOPATHOLOGY; HUMAN; LABORATORY; LYMPH NODE METASTASIS; PATIENT CARE; PROGNOSIS; PUBLICATION; REAL TIME POLYMERASE CHAIN REACTION;

EID: 2442595332     PISSN: 10811672     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Slamon DJ, Leyland_Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92.
2. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M: Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20: 719-26.
3. Cardoso F, Piccart MJ, Durbecq V, Di Leo A: Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 2002;3:247-57; discussion 258-9.
4. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
5. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
6. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat P, Fox SB, Harris AL, Liu ET: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci U S A 2003;100: 10393-8.
7. Frank SG, Bernard, P.S.: Profiling Breast Cancer using Real-Time Quantitative PCR. In: Rapid Cycle Real-Time PCR Methods and Applications, pp 95-106. Ed by W S. Meuer, C., Nakagawara, K. Heidelberg, Germany, Springer, 2003.
8. Bernard PS, Wittwer CT: Real-time PCR technology for cancer diagnostics. Clin Chem 2002;48:1178-85.
9. Cronin M, Pho M, Dutta D, Stephans JC, Shak S, Kiefer MC, Esteban JM, Baker JB: Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay. Am J Pathol 2004;164:35-42.
10. Lewis F, Maughan NJ, Smith V, Hillan K, Quirke P: Unlocking the archive-gene expression in paraffin-embedded tissue. J Pathol 2001;195:66-71.
11. Lehmann U, Kreipe H: Real-time PCR analysis of DNA and RNA extracted from formalin-fixed and paraffin-embedded biopsies. Methods 2001;25:409-18.
12. Vincek V, Nassiri M, Nadji M, Morales AR: A tissue fixative that protects macromolecules (DNA, RNA, and protein) and histomorphology in clinical samples. Lab Invest 2003;83:1427-35.
13. Tebo J, Der S, Frevel M, Khabar KS, Williams BR, Hamilton TA: Heterogeneity in control of mRNA stability by AU-rich elements. J Biol Chem 2003;278:12085-93.
14. Bilous M, Dowsett M, Hanna W, Isola J, Lebeau A, Moreno A, Penault-Llorca F, Ruschoff J, Tomasic G, Van De Vijver M: Current Perspectives on HER2 Testing: A Review of National Testing Guidelines. Mod Pathol 2003;16:173-82.
15. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000;406:747-52.
16. Pollack JR, Sorlie T, Perou CM, Rees CA, Jeffrey SS, Lonning PE, Tibshirani R, Botstein D, Borresen-Dale AL, Brown PO: Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
17. Fiddes RJ, Campbell DH, Janes PW, Sivertsen SP, Sasaki H, Wallasch C, Daly RJ: Analysis of Grb7 recruitment by heregulin-activated erbB receptors reveals a novel target selectivity for erbB3. J Biol Chem 1998;273:7717-24.
18. Hyman E, Kauraniemi P, Hautaniemi S, Wolf M, Mousses S, Rozenblum E, Ringner M, Sauter G, Monni O, Elkahloun A, Kallioniemi OP, Kallioniemi A: Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62: 6240-5.
19. Borreson A-L, Hovig, E., Smith-Sorenson, B., Malkin, D., Lystad, S, Andersoen, T. I., et al: Constant denaturant gel electrophoresis as a rapid screening technique for p53 mutations. Proc Natl Acad Sci U S A 1991;88:8405-8409.
20. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen-Logmans SC, van Staveren IL, van Putten WL, Inganas M, Meijer-van Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
21. Iacopetta B, Grieu F, Powell B, Soong R, McCaul K, Seshadri R: Analysis of p53 gene mutation by polymerase chain reaction-single strand conformation polymorphism provides independent prognostic information in node-negative breast cancer. Clin Cancer Res 1998;4:1597-602.
22. Geisler S, Lonning PE, Aas T, Johnsen H, Fluge Ø, Faksvåg Haugen DH, Lillehaug JR, Akslen LA, Bø rresen-Dale A-L: OLD-Influence of TP53 Gene Alterations and c-erbB-2 Expression on the Response to Treatment with Doxorubicin in Locally Advanced Breast Cancer. Cancer Res 2001;61:2502-2512.
23. Berns EM, Foekens JA, Vossen R, Look MP, Devilee P, Henzen_Logmans SC, van_Staveren IL, van_Putten WL, Inganas M, Meijer_van_Gelder ME, Cornelisse C, Claassen CJ, Portengen H, Bakker B, Klijn JG: Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res 2000;60:2155-62.
24. Bennett CD, Campbell MN, Cook CJ, Eyre DJ, Nay LM, Nielsen DR, Rasmussen RP, Bernard PS: The LightTyper: high-throughput genotyping using fluorescent melting curve analysis. Biotechniques 2003;34:1288-92, 1294-5.
25. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor RJ: High-Resolution Genotyping by Amplicon Melting Analysis Using LCGreen. Clin Chem 2003;49:853-60.
26. Millward H, Samowitz W, Wittwer CT, Bernard PS: Homogeneous Amplification and Mutation Scanning of the p53 Gene Using Fluorescent Melting Curves. Clin Chem 2002;48:1321-1328.